 Jaime Belkind-Gerson
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enteric Nervous System | 11 | 2022 | 26 | 3.780 |
Why?
| | Neural Stem Cells | 9 | 2020 | 115 | 3.090 |
Why?
| | Constipation | 9 | 2022 | 75 | 2.460 |
Why?
| | Neurogenesis | 7 | 2020 | 102 | 2.260 |
Why?
| | Manometry | 8 | 2020 | 88 | 1.640 |
Why?
| | Defecation | 3 | 2019 | 17 | 1.550 |
Why?
| | Rectum | 5 | 2020 | 151 | 1.480 |
Why?
| | Anal Canal | 7 | 2022 | 83 | 1.410 |
Why?
| | Myelin Proteolipid Protein | 2 | 2022 | 61 | 1.400 |
Why?
| | Gastrointestinal Motility | 4 | 2022 | 25 | 1.380 |
Why?
| | Gastroenterology | 6 | 2021 | 158 | 1.280 |
Why?
| | Neuroglia | 8 | 2022 | 150 | 1.260 |
Why?
| | Gastrointestinal Diseases | 4 | 2021 | 184 | 1.150 |
Why?
| | Diarrhea | 16 | 2014 | 173 | 1.140 |
Why?
| | Neurons | 8 | 2022 | 1298 | 1.130 |
Why?
| | Hirschsprung Disease | 6 | 2017 | 87 | 1.050 |
Why?
| | Colitis | 3 | 2019 | 226 | 1.030 |
Why?
| | Intestinal Mucosa | 4 | 2022 | 528 | 1.000 |
Why?
| | Travel | 15 | 2014 | 121 | 1.000 |
Why?
| | Stem Cell Transplantation | 5 | 2017 | 151 | 0.830 |
Why?
| | Botulinum Toxins, Type A | 2 | 2022 | 40 | 0.770 |
Why?
| | Colon | 5 | 2020 | 234 | 0.760 |
Why?
| | Schwann Cells | 1 | 2020 | 27 | 0.740 |
Why?
| | Esophageal Achalasia | 1 | 2020 | 25 | 0.720 |
Why?
| | SOXB1 Transcription Factors | 2 | 2017 | 60 | 0.680 |
Why?
| | Ataxia | 1 | 2019 | 35 | 0.660 |
Why?
| | Pelvic Floor | 1 | 2019 | 24 | 0.660 |
Why?
| | Serotonin 5-HT4 Receptor Agonists | 2 | 2016 | 2 | 0.640 |
Why?
| | Pediatrics | 2 | 2023 | 986 | 0.600 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 30 | 0.580 |
Why?
| | Child | 23 | 2023 | 18488 | 0.560 |
Why?
| | Gastrointestinal Transit | 2 | 2013 | 6 | 0.550 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 269 | 0.530 |
Why?
| | Pressure | 2 | 2014 | 220 | 0.530 |
Why?
| | Escherichia coli Infections | 7 | 2011 | 102 | 0.530 |
Why?
| | Cell Transplantation | 1 | 2016 | 37 | 0.530 |
Why?
| | Child Nutritional Physiological Phenomena | 2 | 2008 | 97 | 0.520 |
Why?
| | Brain | 5 | 2023 | 2370 | 0.520 |
Why?
| | Nerve Regeneration | 3 | 2019 | 53 | 0.500 |
Why?
| | Anesthetics, Intravenous | 1 | 2014 | 27 | 0.460 |
Why?
| | Reflex | 1 | 2014 | 65 | 0.460 |
Why?
| | Propofol | 1 | 2014 | 43 | 0.450 |
Why?
| | Colonoscopy | 1 | 2015 | 204 | 0.430 |
Why?
| | Cell Proliferation | 6 | 2019 | 2194 | 0.400 |
Why?
| | Adult Stem Cells | 2 | 2007 | 32 | 0.350 |
Why?
| | Humans | 49 | 2023 | 115587 | 0.350 |
Why?
| | Animals | 21 | 2022 | 32102 | 0.350 |
Why?
| | Mice, Transgenic | 4 | 2017 | 1970 | 0.350 |
Why?
| | Intestines | 2 | 2019 | 324 | 0.350 |
Why?
| | Mice | 12 | 2022 | 15052 | 0.340 |
Why?
| | Adolescent | 22 | 2020 | 17889 | 0.340 |
Why?
| | Intermediate Filament Proteins | 2 | 2012 | 66 | 0.330 |
Why?
| | Child, Preschool | 10 | 2020 | 9133 | 0.330 |
Why?
| | Gastrointestinal Tract | 3 | 2023 | 168 | 0.330 |
Why?
| | Child Nutrition Disorders | 1 | 2008 | 16 | 0.320 |
Why?
| | Fecal Incontinence | 2 | 2020 | 74 | 0.310 |
Why?
| | Nervous System | 1 | 2008 | 63 | 0.310 |
Why?
| | Nutritional Requirements | 1 | 2008 | 71 | 0.310 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2008 | 85 | 0.300 |
Why?
| | Mexico | 14 | 2014 | 163 | 0.300 |
Why?
| | Nestin | 3 | 2015 | 17 | 0.290 |
Why?
| | Inflammation | 2 | 2017 | 2499 | 0.290 |
Why?
| | Milk, Human | 1 | 2008 | 128 | 0.280 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2008 | 133 | 0.280 |
Why?
| | Retrospective Studies | 9 | 2020 | 12608 | 0.280 |
Why?
| | Nerve Tissue Proteins | 3 | 2013 | 535 | 0.270 |
Why?
| | Escherichia coli | 5 | 2014 | 730 | 0.270 |
Why?
| | Dextran Sulfate | 2 | 2017 | 70 | 0.270 |
Why?
| | Male | 29 | 2021 | 55949 | 0.270 |
Why?
| | Chick Embryo | 3 | 2017 | 122 | 0.260 |
Why?
| | Infant | 8 | 2020 | 7979 | 0.260 |
Why?
| | Stem Cells | 3 | 2007 | 546 | 0.260 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2007 | 239 | 0.260 |
Why?
| | Intestine, Small | 2 | 2021 | 125 | 0.260 |
Why?
| | Irritable Bowel Syndrome | 2 | 2017 | 29 | 0.260 |
Why?
| | Female | 29 | 2021 | 59913 | 0.250 |
Why?
| | Child Welfare | 1 | 2007 | 197 | 0.250 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 4773 | 0.250 |
Why?
| | Spinal Cord Injuries | 1 | 2007 | 173 | 0.240 |
Why?
| | North America | 3 | 2021 | 261 | 0.230 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 214 | 0.230 |
Why?
| | Pancreatic Diseases | 1 | 2004 | 64 | 0.230 |
Why?
| | Capsule Endoscopy | 2 | 2013 | 16 | 0.220 |
Why?
| | Clinical Competence | 2 | 2021 | 912 | 0.220 |
Why?
| | Nervous System Diseases | 1 | 2006 | 253 | 0.220 |
Why?
| | Proteolipids | 1 | 2022 | 28 | 0.210 |
Why?
| | Cell Culture Techniques | 2 | 2012 | 344 | 0.210 |
Why?
| | Infant, Newborn | 6 | 2020 | 5077 | 0.210 |
Why?
| | Toxoplasma | 2 | 2013 | 33 | 0.210 |
Why?
| | Adult | 19 | 2021 | 30718 | 0.200 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2002 | 3 | 0.200 |
Why?
| | Chronic Disease | 4 | 2022 | 1598 | 0.200 |
Why?
| | Cells, Cultured | 6 | 2017 | 3914 | 0.200 |
Why?
| | Isoamylase | 1 | 2001 | 1 | 0.200 |
Why?
| | Cell Differentiation | 5 | 2014 | 1700 | 0.190 |
Why?
| | Botulinum Toxins | 1 | 2022 | 39 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2011 | 1918 | 0.190 |
Why?
| | Trypsin | 1 | 2001 | 67 | 0.190 |
Why?
| | Disease Models, Animal | 5 | 2017 | 3580 | 0.190 |
Why?
| | Astrocytes | 2 | 2013 | 163 | 0.190 |
Why?
| | Societies, Medical | 2 | 2021 | 684 | 0.190 |
Why?
| | Barium | 1 | 2020 | 25 | 0.190 |
Why?
| | Barium Sulfate | 1 | 2020 | 15 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2022 | 9159 | 0.180 |
Why?
| | Cachexia | 1 | 2001 | 52 | 0.180 |
Why?
| | Enema | 1 | 2020 | 38 | 0.180 |
Why?
| | Muscle Spasticity | 1 | 2020 | 53 | 0.170 |
Why?
| | Escherichia coli Proteins | 4 | 2008 | 164 | 0.170 |
Why?
| | Abnormalities, Multiple | 1 | 2001 | 176 | 0.170 |
Why?
| | Pancreas | 1 | 2001 | 280 | 0.160 |
Why?
| | Anorectal Malformations | 1 | 2020 | 104 | 0.160 |
Why?
| | Antibodies, Bacterial | 2 | 2010 | 119 | 0.160 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4440 | 0.160 |
Why?
| | Mice, Knockout | 2 | 2022 | 2604 | 0.160 |
Why?
| | Bone and Bones | 1 | 2001 | 283 | 0.160 |
Why?
| | Enterotoxins | 2 | 2008 | 88 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 930 | 0.150 |
Why?
| | Bacterial Toxins | 2 | 2008 | 103 | 0.150 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 8 | 0.150 |
Why?
| | Curriculum | 2 | 2021 | 852 | 0.150 |
Why?
| | Citrobacter rodentium | 1 | 2017 | 6 | 0.150 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 29 | 0.150 |
Why?
| | Injections | 1 | 2017 | 161 | 0.140 |
Why?
| | Submucous Plexus | 1 | 2017 | 2 | 0.140 |
Why?
| | Myenteric Plexus | 1 | 2017 | 4 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2015 | 1642 | 0.140 |
Why?
| | Intestine, Large | 1 | 2017 | 14 | 0.140 |
Why?
| | Polymerase Chain Reaction | 6 | 2011 | 1000 | 0.140 |
Why?
| | Stem Cell Niche | 1 | 2017 | 43 | 0.140 |
Why?
| | Radionuclide Imaging | 2 | 2013 | 121 | 0.140 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2016 | 7 | 0.140 |
Why?
| | Laxatives | 1 | 2016 | 17 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 241 | 0.130 |
Why?
| | Abdominal Pain | 1 | 2017 | 135 | 0.130 |
Why?
| | Poloxamer | 1 | 2016 | 12 | 0.130 |
Why?
| | Virulence Factors | 2 | 2008 | 139 | 0.130 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 25 | 0.130 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2016 | 57 | 0.130 |
Why?
| | Receptor, Endothelin B | 1 | 2015 | 51 | 0.130 |
Why?
| | Integrin alpha2 | 1 | 2015 | 2 | 0.130 |
Why?
| | Deoxyuridine | 1 | 2015 | 6 | 0.130 |
Why?
| | Mice, 129 Strain | 1 | 2015 | 77 | 0.130 |
Why?
| | Norovirus | 2 | 2005 | 23 | 0.130 |
Why?
| | United States | 11 | 2021 | 12295 | 0.130 |
Why?
| | Delayed-Action Preparations | 1 | 2016 | 159 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 503 | 0.130 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 31 | 0.120 |
Why?
| | Sulfonamides | 2 | 2016 | 447 | 0.120 |
Why?
| | Students, Medical | 1 | 2019 | 277 | 0.120 |
Why?
| | Cystic Fibrosis | 1 | 2004 | 957 | 0.120 |
Why?
| | Providencia | 1 | 2014 | 1 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2014 | 44 | 0.110 |
Why?
| | Defecography | 1 | 2013 | 2 | 0.110 |
Why?
| | Gastroparesis | 1 | 2013 | 8 | 0.110 |
Why?
| | Gastric Emptying | 1 | 2013 | 40 | 0.110 |
Why?
| | Protozoan Proteins | 1 | 2013 | 62 | 0.110 |
Why?
| | Young Adult | 7 | 2020 | 10470 | 0.110 |
Why?
| | Cell Survival | 1 | 2016 | 1024 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 41 | 0.100 |
Why?
| | Research | 2 | 2007 | 396 | 0.100 |
Why?
| | Cell Movement | 1 | 2017 | 867 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1056 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 174 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 398 | 0.100 |
Why?
| | Campylobacter jejuni | 1 | 2010 | 11 | 0.090 |
Why?
| | Brain Injuries | 1 | 2016 | 451 | 0.090 |
Why?
| | Campylobacter Infections | 1 | 2010 | 9 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 81 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2353 | 0.090 |
Why?
| | Immunoglobulins | 1 | 2010 | 147 | 0.090 |
Why?
| | Mice, Inbred BALB C | 3 | 2013 | 1168 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2009 | 23 | 0.080 |
Why?
| | Dichlorodiphenyl Dichloroethylene | 1 | 2008 | 3 | 0.080 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1405 | 0.080 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 13 | 0.080 |
Why?
| | Escherichia coli Vaccines | 1 | 2008 | 3 | 0.080 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2008 | 3 | 0.080 |
Why?
| | Occult Blood | 1 | 2008 | 27 | 0.080 |
Why?
| | Cell Lineage | 2 | 2014 | 310 | 0.080 |
Why?
| | Quadriplegia | 1 | 2007 | 12 | 0.080 |
Why?
| | Infant Formula | 1 | 2008 | 74 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 4 | 2011 | 795 | 0.070 |
Why?
| | Rifamycins | 1 | 2007 | 5 | 0.070 |
Why?
| | Loperamide | 1 | 2007 | 10 | 0.070 |
Why?
| | Maternal Exposure | 1 | 2008 | 138 | 0.070 |
Why?
| | Lactoferrin | 1 | 2007 | 28 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1122 | 0.070 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 73 | 0.070 |
Why?
| | Digestive System Physiological Phenomena | 1 | 2006 | 2 | 0.070 |
Why?
| | Feces | 4 | 2011 | 372 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2008 | 299 | 0.070 |
Why?
| | Global Health | 1 | 2008 | 290 | 0.070 |
Why?
| | Intestinal Diseases | 1 | 2006 | 29 | 0.070 |
Why?
| | Caliciviridae Infections | 1 | 2005 | 17 | 0.060 |
Why?
| | Neural Crest | 1 | 2007 | 117 | 0.060 |
Why?
| | Liver Diseases | 1 | 2008 | 263 | 0.060 |
Why?
| | Developing Countries | 1 | 2006 | 240 | 0.060 |
Why?
| | Spinal Cord | 1 | 2007 | 351 | 0.060 |
Why?
| | Antiparasitic Agents | 1 | 2004 | 3 | 0.060 |
Why?
| | Students | 2 | 2008 | 502 | 0.060 |
Why?
| | Albendazole | 1 | 2004 | 4 | 0.060 |
Why?
| | Intestinal Diseases, Parasitic | 1 | 2004 | 11 | 0.060 |
Why?
| | Anthelmintics | 1 | 2004 | 9 | 0.060 |
Why?
| | Biofilms | 1 | 2006 | 222 | 0.060 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 225 | 0.060 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2004 | 2 | 0.060 |
Why?
| | Gastroesophageal Reflux | 1 | 2007 | 235 | 0.060 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 73 | 0.060 |
Why?
| | Thiazoles | 1 | 2004 | 110 | 0.060 |
Why?
| | Middle Aged | 9 | 2010 | 26999 | 0.060 |
Why?
| | Coloring Agents | 1 | 2004 | 71 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2014 | 79 | 0.060 |
Why?
| | International Cooperation | 1 | 2004 | 174 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2007 | 684 | 0.050 |
Why?
| | Embryo, Nonmammalian | 1 | 2003 | 173 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2003 | 214 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2009 | 2125 | 0.050 |
Why?
| | Central Nervous System | 1 | 2004 | 239 | 0.050 |
Why?
| | Biomarkers | 2 | 2014 | 3466 | 0.050 |
Why?
| | Nutrition Disorders | 1 | 2001 | 23 | 0.050 |
Why?
| | Dwarfism | 1 | 2001 | 15 | 0.050 |
Why?
| | Leukemia, Myeloid | 1 | 2001 | 40 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1718 | 0.050 |
Why?
| | Immunoglobulin G | 3 | 2010 | 781 | 0.050 |
Why?
| | Neutropenia | 1 | 2001 | 127 | 0.050 |
Why?
| | Hematopoietic Stem Cells | 1 | 2003 | 346 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2001 | 286 | 0.050 |
Why?
| | Syndrome | 1 | 2001 | 339 | 0.040 |
Why?
| | Pregnancy | 2 | 2008 | 5548 | 0.040 |
Why?
| | Bone Marrow | 1 | 2001 | 249 | 0.040 |
Why?
| | Temperature | 2 | 2016 | 587 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2004 | 691 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 238 | 0.040 |
Why?
| | Shock, Septic | 1 | 2001 | 185 | 0.040 |
Why?
| | Rats | 1 | 2007 | 5034 | 0.040 |
Why?
| | Calcinosis | 1 | 2001 | 242 | 0.040 |
Why?
| | Canada | 2 | 2011 | 335 | 0.040 |
Why?
| | Acute Disease | 1 | 2001 | 914 | 0.040 |
Why?
| | Esophagus | 1 | 2020 | 226 | 0.040 |
Why?
| | Celiac Disease | 1 | 2001 | 266 | 0.040 |
Why?
| | Poverty | 1 | 2001 | 448 | 0.040 |
Why?
| | Virulence | 2 | 2008 | 231 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2017 | 57 | 0.030 |
Why?
| | Risk Assessment | 3 | 2014 | 2987 | 0.030 |
Why?
| | Prognosis | 1 | 2004 | 3339 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2004 | 2574 | 0.030 |
Why?
| | Transplantation, Isogeneic | 1 | 2015 | 17 | 0.030 |
Why?
| | Cohort Studies | 3 | 2011 | 4944 | 0.030 |
Why?
| | Risk Factors | 4 | 2010 | 8697 | 0.030 |
Why?
| | Guatemala | 2 | 2008 | 268 | 0.030 |
Why?
| | Reference Values | 2 | 2007 | 744 | 0.030 |
Why?
| | Physician's Role | 1 | 2017 | 199 | 0.030 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 74 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 376 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2578 | 0.030 |
Why?
| | Time Factors | 3 | 2014 | 6165 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1227 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2016 | 120 | 0.030 |
Why?
| | Calbindin 2 | 1 | 2014 | 8 | 0.030 |
Why?
| | Liposomes | 1 | 2016 | 149 | 0.030 |
Why?
| | Synaptophysin | 1 | 2014 | 11 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2014 | 15 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 34 | 0.030 |
Why?
| | Cell Shape | 1 | 2014 | 54 | 0.030 |
Why?
| | S100 Proteins | 1 | 2014 | 39 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 248 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3022 | 0.030 |
Why?
| | Tubulin | 1 | 2014 | 123 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2008 | 1660 | 0.030 |
Why?
| | Genes, bcl-2 | 1 | 2013 | 20 | 0.030 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2013 | 60 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2013 | 42 | 0.030 |
Why?
| | Sex Factors | 2 | 2008 | 1736 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2014 | 121 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2651 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2013 | 88 | 0.030 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 40 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 450 | 0.030 |
Why?
| | Aged | 2 | 2007 | 19251 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1856 | 0.030 |
Why?
| | Nanoparticles | 1 | 2016 | 316 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 214 | 0.020 |
Why?
| | Caspases | 1 | 2013 | 245 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 263 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2011 | 189 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 286 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 780 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2013 | 369 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 27 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 299 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 2010 | 173 | 0.020 |
Why?
| | Pancreas Transplantation | 1 | 1989 | 64 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 316 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 254 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 4435 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1180 | 0.020 |
Why?
| | Endocrine System | 1 | 2008 | 20 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 11 | 0.020 |
Why?
| | Serologic Tests | 1 | 2008 | 51 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 116 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2008 | 69 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2008 | 127 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 65 | 0.020 |
Why?
| | Prospective Studies | 2 | 2011 | 6264 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2008 | 78 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 499 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4665 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 156 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2008 | 309 | 0.020 |
Why?
| | Probability | 1 | 2007 | 294 | 0.020 |
Why?
| | Graft Rejection | 1 | 1989 | 533 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 959 | 0.020 |
Why?
| | Seasons | 1 | 2008 | 449 | 0.020 |
Why?
| | Odds Ratio | 1 | 2008 | 962 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 66 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 724 | 0.020 |
Why?
| | Nitro Compounds | 1 | 2004 | 6 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 776 | 0.010 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2006 | 284 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 962 | 0.010 |
Why?
| | Trans-Activators | 1 | 2006 | 370 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2377 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1377 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1440 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1870 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1893 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 734 | 0.010 |
Why?
| | Phylogeny | 1 | 2005 | 805 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 2907 | 0.010 |
Why?
| | Incidence | 1 | 2007 | 2335 | 0.010 |
Why?
| | Genotype | 1 | 2005 | 1786 | 0.010 |
Why?
| | Dogs | 1 | 1989 | 341 | 0.000 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1989 | 161 | 0.000 |
Why?
| | Glucose Tolerance Test | 1 | 1989 | 344 | 0.000 |
Why?
| | Blood Glucose | 1 | 1989 | 1824 | 0.000 |
Why?
|
|
Belkind-Gerson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|